Dendreon

Dendreon is a biotechnology company focused on transforming lives by discovering, developing, and commercializing novel cancer therapies. Dendreon applies its expertise in antigen identification and cell processing to produce Active Cellular Immunotherapy (ACI) candidates designed to stimulate an immune response. The prospects for ACI are promising as it can deliver meaningful clinical benefits to patients, such as survival and low toxicity. In addition to ACI candidates, the company is also developing an orally administered small molecule drug targeting TRPM8, which may be used for various cancers as well as benign prostatic hyperplasia.